ribupatide
AssetAlso KAI-9531, HRS9531
Dual GLP-1 and GIP receptor agonist for metabolic disorders and weight loss
- Stage
- Phase 3
- Modality
- Peptide
- Target
- Insulin/IGF-1 signalling
- 7
- Indications
- 4
- Trials
- 2
- Developers
Indications
7Obesity
Phase 3, Active not recruiting, NCT07284875, clinicaltrials.gov, 7 Oct 2026
Obesity with diabetes
Phase 3, Active not recruiting, NCT07284901, clinicaltrials.gov, 7 Oct 2026
Overweight
Phase 3, Active not recruiting, NCT07284875, clinicaltrials.gov, 7 Oct 2026
4 more
In the full profile
- Targets and what it contains6
- Owner and partners2
- Trials4
- Evidence for its targets7
- Competitors12
- Aging relevance1
- Signals10
Every asset’s record: target, stage, trials and the evidence behind it.